Trial Profile
Multiple ascending dose study of NBI-640756 for the treatment of essential tremor.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2017
Price :
$35
*
At a glance
- Drugs NBI 640756 (Primary)
- Indications Essential tremor
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Neurocrine Biosciences
- 14 Feb 2017 According to Neuroendocrine Biosciences media release, data from this study is expected later in 2017.
- 03 Aug 2016 According to Neuroendocrine Biosciences media release, the results from this study are expected later in 2016.
- 03 Aug 2016 According to Neuroendocrine Biosciences media release, planned number of patients changed to 30.